- Home
- PFIS vs ADCT Comparison
PFIS vs ADCT Comparison
Compare PFIS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFIS | ADCT |
|---|---|---|
| Founded | 1905 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.8M | 484.4M |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PFIS | ADCT |
|---|---|---|
| Price | $54.62 | $3.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $56.00 | $7.75 |
| AVG Volume (30 Days) | 39.1K | ★ 759.1K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.58% | N/A |
| EPS Growth | ★ 493.94 | 30.86 |
| EPS | ★ 5.88 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $5.85 | $66.49 |
| P/E Ratio | $9.29 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $39.05 | $1.05 |
| 52 Week High | $57.71 | $4.98 |
Technical Indicators
Market Signals| Indicator | PFIS | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 43.30 |
| Support Level | $49.98 | $3.65 |
| Resistance Level | $57.71 | $3.87 |
| Average True Range (ATR) | 1.52 | 0.21 |
| MACD | 0.29 | -0.04 |
| Stochastic Oscillator | 95.06 | 29.73 |
Price Performance
Historical ComparisonAbout PFIS Peoples Financial Services Corp.
Peoples Financial Services Corp is a bank holding company operating through its subsidiaries. The bank provides a full range of financial services. Its products and services include checking accounts, business accounts, savings accounts, loan products, money market accounts, mortgages, chip-enabled debit cards, credit card processing, and visa master card and advisory services. Its loan portfolio includes Commercial loans, which consist of commercial, commercial real estate, municipal, and other related tax-free loans; and retail loans, which include residential real estate and other consumer loans. The company mainly operates in the United States in Pennsylvania.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).